Please login to the form below
Scottish Medicines Consortium
This page shows the latest Scottish Medicines Consortium news and features for those working in and with pharma, biotech and healthcare.
Shionogi launches thrombocytopenia treatment Mulpleo in the UK
The UK’s medicines watchdog NICE and the Scottish Medicines Consortium recently backed the use of Mulpleo in this patient population after determining that the drug was cost-effective.
Latest news
-
SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease
Drug is being reviewed under new ultra-orphan pathway. The Scottish Medical Consortium has enabled access to Japanese pharma Kyowa Kirin's Crysvita, a novel treatment for a rare inherited bone ... England’s cost-effectiveness watchdog NICE issued a
-
Diurnal files adrenal insufficiency drug Alkindi in US
It has since been backed by the Scottish Medicines Consortium (SMC) for reimbursement on the NHS.
-
Vertex scores CF deal with Scotland, but access debate continues
Pressure to reach a deal in England mounts. Following an initial rejection from the Scottish Medicines Consortium (SMC), Vertex has reached an agreement for all eligible cystic fibrosis patients living in ... The agreement has been reached after
-
Novartis’ CAR-T Kymriah scores SMC approval
Will now be available on NHS across the UK. Novartis’ Kymriah (tisagenlecleucel) has received routine reimbursement for all eligible UK patients on the NHS, following appraisal from the Scottish Medicines Consortium. . ... treatments. The medicine
-
NICE backs NHS use of Novartis’ gene therapy Luxturna
The Scottish Medicines Consortium (SMC) is due to deliver its verdict on the gene therapy in December.
More from news
Approximately 5 fully matching, plus 87 partially matching documents found.
Latest Intelligence
-
The Orkambi row explained
December 2018: Scottish Government agrees a deal with Vertex pending submission of Orkambi and Symkevi to Scottish Medicines Consortium (SMC), with interim access possible through the PACS Tier 2 system. ... March 2019: Vertex, NHSE and NICE meet with
-
The reality of real-world evidence
Zaltrap re-submission to the Scottish Medicines Consortium (SMC) included RWE (pooled data from two open-label, single-arm studies) to demonstrate prolonged safety and QoL benefit.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- FDA hands BMS and bluebird bio a priority review for ide-cel
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
- Q&A: Isabel Gibson
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
